Nothing Special   »   [go: up one dir, main page]

AR030432A1 - Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica. - Google Patents

Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica.

Info

Publication number
AR030432A1
AR030432A1 ARP010103092A ARP010103092A AR030432A1 AR 030432 A1 AR030432 A1 AR 030432A1 AR P010103092 A ARP010103092 A AR P010103092A AR P010103092 A ARP010103092 A AR P010103092A AR 030432 A1 AR030432 A1 AR 030432A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
defined above
represents hydrogen
hydrogen
Prior art date
Application number
ARP010103092A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR030432A1 publication Critical patent/AR030432A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

El uso de derivados de quinazolina de formula (1) o una sal, éster o amida del mismo; en la cual X es O, o S, S(O) o S(O)2, o NR6 donde R6 es hidrogeno o alquilo C1-6; R5 es un anillo heteroaromático de 5 miembros opcionalmente sustituido, R1, R2, R3, R4 están independientemente seleccionados entre halo, ciano, nitro, trifluormetilo, alquilo C1-3, NR7R8 (donde R7 y R8 que pueden ser iguales o diferentes, representan cada uno hidrogeno o alquilo C1-3), o -X1R9 (donde X1 representa un enlace directo, -O-, -CH2-, -OCO-, carbonilo, -S-, -SO-, -SO2-, -NR10CO-, -CONR11-, -SO2NR12-, -NR13SO2-, o NR14 - (donde R10, R11, R12, R13 y R14 representa cada uno independientemente hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3), y R9 está seleccionado entre uno de los siguientes grupos: 1) hidrogeno o alquilo C1-5 que puede estar no sustituido o puede estar sustituido con uno o más grupos seleccionados de hidroxi, fluor o amino, 2) alquilo C1-5X2COR15 (donde X2 representa -O- o -NR16- (en el cual R15 representa hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3 y R16 representa alquilo C1-3, -NR17R18 o -OR19 (donde R17, R18 y R19, que pueden ser iguales o diferentes, representan cada uno hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3)); 3) alquilo C1-5X3R20 (donde X3 representa -O-, -S-, -SO-, -SO2-, -OCO-, -NR21CO-, -CONR22-, -SO2NR23-, -NR24SO2- o -NR25- (donde R21, R22, R23, R24 y R25 representa cada uno independientemente hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R20 representa hidrogeno, alquilo C1-3, ciclopentilo, ciclohexilo o un grupo heterocíclico saturado de 5-6 miembros con 1-2 heteroátomos, seleccionados independientemente de O, S y N, donde el grupo alquilo C1-3 puede ser portador de 1 o 2 sustituyentes seleccionados de oxo, hidroxi, halogeno y alcoxi C1-4 y donde el grupo cíclico puede ser portador de uno o dos sustituyentes seleccionados de oxo, hidroxi, halogeno, alquilo C1-4, hidroxialquilo C1-4, y alcoxi C1-4; 4) alquilo C1-5 X4 alquilo C1-5 X5R26 (donde X4 y X5, que pueden ser iguales o diferentes, son cada uno -O-, -S-, -SO-, -SO2-, -NR27CO-, -CONR28-, -SO2NR29-, -NR30SO2- o -NR31- (donde R27, R28, R29, R30 y R31 cada uno independientemente representa hidrogeno, alquilo C1-3 y alcoxi C1-3 alquilo C2-3) y R26 representa hidrogeno o alquilo C1-3); 5) R32 (donde R32 es un grupo heterocíclilo saturado de 5-6 miembros (ligado a través de carbono o nitrogeno) con 1-2 heteroátomos, seleccionados independientemente de O, S y N, donde el grupo heterocíclico puede ser portador de uno o dos sustituyentes seleccionados de oxo, hidroxi, halogeno, alquilo C1-4, hidroxialquilo C1-4, alcoxi C1-4, alcoxi C1-4 alquilo C1-4 y alquilsulfonil C1-4 alquilo C1-4); 6) alquilo C1-5 R32 (donde R32 es tal como se ha definido anteriormente); 7) alquenilo C2-5 R32 (donde R32 es tal como se ha definido anteriormente); 8) alquinilo C2-5R32 (donde R32 es tal como se ha definido anteriormente); 9) R33 (donde R33 representa un grupo piridona, fenilo o un grupo heterocíclico aromático de 5-6 miembros (ligado a través de carbono o nitrogeno) con 1-3 heterátomos seleccionados de O, N y S, donde el grupo piridona, fenilo o heterocíclico aromático puede ser portador de hasta 5 sustituyentes sobre un átomo de carbono asequible, seleccionados de hidroxi, halogeno, amino, alquilo C1-4, alcoxi C1-4, hidroxialquilo C1-4, aminoalquilo C1-4, alquilamino C1-4, hidroxialcoxi C1-4, carboxi, trifluormetilo, ciano, -CONR34R35 y -NR36COR37 (donde R34, R35,R36 y R37, que pueden ser iguales o diferentes, representa cada uno hidrogeno, alquilo C1-4 o alcoxi C1-3 alquilo C2-3)); 10) alquilo C1-5R33 (donde R33 es tal como se ha definido anteriormente); 11) alquenilo C2-5 R33(donde R33 es tal como se ha definido anteriormente); 12) alquinilo C2-5R33 (donde R33 es tal como se ha definido anteriormente); 13) alquilo C1-5X6R33 (donde X6 representa -O-, -S-, -SO2-, -NR38CO-, -CONR39-, -SO2NR40-, -NR41SO2- o -NR42- (donde R38, R39, R40, R41 y R42 representa cada uno independientemente hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R33 es tal como se ha definido anteriormente); 14) alquenilo C2-5X7R33 (donde X7 representa -O-, -S-, -SO-, -SO2-, -NR43CO-, -CONR44-, -SO2NR45, -NR46SO2-, o -NR47- (donde R43, R44, R45, R46 y R47 cada uno independientemente representa hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R33 es tal como se ha definido anteriormente); 15) alquinilo C2-5X8R33 (donde X8 representa -O-, -S-, -SO-, -SO2-, -NR48CO-, -CONR49-, -SO2NR50-, -NR51SO2- o -NR52- (donde R48, R49, R50, R51 y R52 cada uno independientemente representa hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R33 es tal como se ha definido anteriormente); 16) alquilo C1-3X9 alquilo C1-3R33 (donde X9 representa -O-, -S-, -SO-, -SO2-, -NR53CO-, -CONR54-, -SO2NR55-, -NR56SO2- o -NR57- (donde R53, R54, R55, R56 y R57 cada uno de los cuales representa independientemente hidrogeno, alquilo C1-3 o alcoxi C1-3 alquilo C2-3) y R33 es tal como se ha definido anteriormente) y 17) alquilo C1-3X9 alquilo C1-3R32 (donde X9 y R28 son tal como se han definido anteriormente); que se usa en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmacéutica.
ARP010103092A 2000-06-28 2001-06-28 Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica. AR030432A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00401842 2000-06-28

Publications (1)

Publication Number Publication Date
AR030432A1 true AR030432A1 (es) 2003-08-20

Family

ID=8173742

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103092A AR030432A1 (es) 2000-06-28 2001-06-28 Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica.

Country Status (27)

Country Link
US (2) US6919338B2 (es)
EP (1) EP1299381B1 (es)
JP (1) JP2004501914A (es)
KR (1) KR20030014411A (es)
CN (1) CN1267431C (es)
AR (1) AR030432A1 (es)
AT (1) ATE394102T1 (es)
AU (1) AU2001266505A1 (es)
BG (1) BG107376A (es)
BR (1) BR0111754A (es)
CA (1) CA2412592A1 (es)
CZ (1) CZ20024120A3 (es)
DE (1) DE60133897D1 (es)
EE (1) EE200200715A (es)
ES (1) ES2305081T3 (es)
HK (1) HK1053124A1 (es)
HU (1) HUP0301236A2 (es)
IL (1) IL153246A0 (es)
IS (1) IS6656A (es)
MX (1) MXPA02011974A (es)
NO (1) NO20026010L (es)
NZ (1) NZ522696A (es)
PL (1) PL360439A1 (es)
RU (1) RU2283311C2 (es)
SK (1) SK18102002A3 (es)
WO (1) WO2002000649A1 (es)
ZA (1) ZA200209412B (es)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002022602A2 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Triazole compounds useful as protein kinase inhibitors
ES2266095T3 (es) * 2000-12-21 2007-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de la proteina quinasa.
CN100491372C (zh) * 2001-12-24 2009-05-27 阿斯特拉曾尼卡有限公司 作为欧若拉激酶抑制剂的取代喹唑啉衍生物
AU2003215087B2 (en) * 2002-02-06 2009-07-16 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of GSK-3
DK1482931T3 (da) * 2002-03-05 2011-12-19 Transtech Pharma Inc Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE
US20040009981A1 (en) * 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
CA2485429A1 (en) * 2002-05-06 2004-07-15 Vertex Pharmaceuticals Incorporated Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
ES2400339T3 (es) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
PT1532145E (pt) * 2002-08-02 2007-01-31 Vertex Pharma Composiçoes de pirazole úteis como inibidores de gsk-3
GB0221245D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Chemical process
UA86470C2 (ru) * 2002-12-24 2009-04-27 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
RU2357971C2 (ru) 2002-12-24 2009-06-10 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
CA2508921A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Quinazoline compounds
US7601718B2 (en) * 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
CN1809557B (zh) * 2003-04-16 2012-07-04 阿斯利康(瑞典)有限公司 化合物
MXPA05012350A (es) * 2003-05-20 2006-05-25 Transtech Pharma Inc Antagonistas rage como agentes para la amiloidosis inversa y enfermedades asociadas con la misma.
WO2004105764A1 (en) * 2003-06-02 2004-12-09 Astrazeneca Ab (3- ((quinazolin-4-yl) amino )-1h-pyrazol-1-yl) acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
GB0320793D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Chemical process
EP1673085B1 (en) 2003-09-26 2011-11-09 Exelixis, Inc. C-met modulators and methods of use
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20090143399A1 (en) * 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20080051414A1 (en) * 2003-10-14 2008-02-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
WO2005037825A2 (en) * 2003-10-14 2005-04-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein kinase inhibitors
JP2007509985A (ja) * 2003-10-31 2007-04-19 ニューロジェン・コーポレーション カプサイシン受容体作動薬
CN1902193B (zh) * 2003-12-04 2011-07-13 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的喹喔啉
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
US8119684B2 (en) * 2003-12-30 2012-02-21 Dana-Farber Cancer Institute, Inc. Thiophene derivatives for up-regulating HLA-DM activity
CN1934100A (zh) * 2004-03-23 2007-03-21 万有制药株式会社 取代喹唑啉或吡啶并嘧啶衍生物
JP2007533753A (ja) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
WO2006023931A2 (en) * 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
US20090036485A1 (en) * 2004-10-12 2009-02-05 Frederic Henri Jung Quinoline derivatives
CN101072758B (zh) * 2004-10-12 2013-07-31 阿斯利康(瑞典)有限公司 喹唑啉衍生物
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN1854130B (zh) * 2005-04-15 2011-04-20 中国医学科学院药物研究所 喹唑啉衍生物、及其制法和药物组合物与用途
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
AU2006279376B2 (en) * 2005-08-18 2011-04-14 Vertex Pharmaceuticals Incoporated Pyrazine kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200736250A (en) * 2005-11-03 2007-10-01 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
EP1785420A1 (en) * 2005-11-14 2007-05-16 4Sc Ag Thiazole analogues and uses thereof
CA2637658C (en) 2006-01-23 2012-07-17 Amgen Inc. Aurora kinase modulators and method of use
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
US7868177B2 (en) * 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
EP1994024A2 (en) * 2006-03-02 2008-11-26 AstraZeneca AB Quinoline derivatives
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2007113005A2 (en) * 2006-04-03 2007-10-11 European Molecular Biology Laboratory (Embl) 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
US20080207632A1 (en) * 2006-10-31 2008-08-28 Supergen, Inc. Protein kinase inhibitors
MX2009004807A (es) * 2006-11-02 2009-06-15 Vertex Pharma Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
EP2099787B1 (en) * 2006-12-19 2010-07-21 Vertex Pharmaceuticals, Inc. Aminopyrimidines useful as inhibitors of protein kinases
NZ579446A (en) * 2007-03-09 2012-02-24 Vertex Pharma Aminopyrimidines useful as inhibitors of protein kinases
ATE526328T1 (de) * 2007-03-09 2011-10-15 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyrimidine
EP2134709A1 (en) * 2007-03-09 2009-12-23 Vertex Pharmaceuticals, Inc. Aminopyridines useful as inhibitors of protein kinases
ES2470341T3 (es) 2007-04-05 2014-06-23 Amgen, Inc Moduladores de la aurora cinasa y método de uso
NZ580343A (en) 2007-04-13 2012-03-30 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
NZ580884A (en) * 2007-05-02 2012-02-24 Vertex Pharma Thiazoles and pyrazoles useful as kinase inhibitors
AU2008247595A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
JP5389786B2 (ja) * 2007-05-02 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害として有用なアミノピリミジン
GB0709031D0 (en) * 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
EP2164842A2 (en) * 2007-05-24 2010-03-24 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
JP5478488B2 (ja) * 2007-06-20 2014-04-23 メルク・シャープ・アンド・ドーム・コーポレーション Janusキナーゼの阻害剤
CA2691100A1 (en) * 2007-06-21 2008-12-24 Irm Llc Protein kinase inhibitors and methods for using thereof
JP5553751B2 (ja) * 2007-07-31 2014-07-16 バーテックス ファーマシューティカルズ インコーポレイテッド 5−フルオロ−1H−ピラゾロ[3,4−b]ピリジン−3−アミンおよびその誘導体を調製するためのプロセス
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
JP2011515401A (ja) * 2008-03-20 2011-05-19 アムジエン・インコーポレーテツド オーロラキナーゼモジュレーターおよび使用方法
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use
CN102215816A (zh) * 2008-09-03 2011-10-12 沃泰克斯药物股份有限公司 共晶和包含所述共晶的药物制剂
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
CA2995883C (en) 2008-12-03 2023-01-24 The Scripps Research Institute Compounds and methods for stabilizing cell cultures
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc N-(4-{〔6,7雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽及其結晶型
EP2396307B1 (en) * 2009-02-11 2014-10-15 Merck Patent GmbH Novel amino azaheterocyclic carboxamides
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
TWI517850B (zh) 2009-09-30 2016-01-21 Vtv治療有限責任公司 經取代之咪唑衍生物及其使用方法
ES2559209T3 (es) 2010-04-14 2016-02-11 Bristol-Myers Squibb Company Nuevos activadores de la glucocinasa y métodos de uso de los mismos
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
BR112013011689A2 (pt) 2010-11-18 2017-10-17 Kasina Laila Innova Pharmaceuticals Private Ltd compostos e métodos de uso do 4-(selenofeno-2(ou 3)-ilamino) pirimidina substituído
US8785459B2 (en) * 2011-12-27 2014-07-22 Development Center For Biotechnology Quinazoline compounds as kinase inhibitors
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
PL2634185T3 (pl) 2012-03-02 2016-06-30 Sareum Ltd Inhibitory kinazy TYK2
CN103788085B (zh) * 2012-10-31 2016-09-07 复旦大学 2-(喹唑啉-4-氨基)-5-噻唑甲酰胺类衍生物及其生物药物用途
CN104098551B (zh) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
SI3311845T1 (sl) 2013-09-16 2020-06-30 Astrazeneca Ab Terapevtski polimerni nanodelci in postopki njihove izdelave in uporabe
CA3000988A1 (en) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
EP4025565A1 (en) * 2019-09-06 2022-07-13 Inflazome Limited Nlrp3 inhibitors
CN110746398A (zh) * 2019-10-18 2020-02-04 刘沛友 4-杂环取代喹唑啉类衍生物及其制备方法和用途
CN111574473A (zh) * 2020-06-04 2020-08-25 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 一种氨基噻唑类化合物的合成方法
CN113311166B (zh) * 2021-04-28 2022-10-28 新疆农垦科学院 一种用于绵羊早期妊娠诊断的蛋白生物标志物及其用于绵羊早期妊娠检测的方法
CN115557601B (zh) * 2022-11-08 2024-11-08 成都理工大学 生物质微球及其制备方法与应用、生物反应器、地下井
WO2024184550A1 (en) * 2023-03-09 2024-09-12 Cancer Research Technology Limited Biarylamide derivatives and their use as pkmyt1 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870725A (en) * 1971-03-30 1975-03-11 Lilly Industries Ltd Nitrothiazole derivatives
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
IL117620A0 (en) * 1995-03-27 1996-07-23 Fujisawa Pharmaceutical Co Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
JP2002527436A (ja) * 1998-10-08 2002-08-27 アストラゼネカ アクチボラグ キナゾリン誘導体
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
DE60133897D1 (de) 2008-06-19
EP1299381A1 (en) 2003-04-09
IS6656A (is) 2002-12-17
PL360439A1 (en) 2004-09-06
BR0111754A (pt) 2003-04-29
US6919338B2 (en) 2005-07-19
US20060046987A1 (en) 2006-03-02
CN1267431C (zh) 2006-08-02
JP2004501914A (ja) 2004-01-22
ES2305081T3 (es) 2008-11-01
RU2283311C2 (ru) 2006-09-10
US20030187002A1 (en) 2003-10-02
NZ522696A (en) 2004-08-27
CZ20024120A3 (cs) 2003-03-12
EP1299381B1 (en) 2008-05-07
HUP0301236A2 (hu) 2003-10-28
WO2002000649A9 (en) 2007-09-20
CA2412592A1 (en) 2002-01-03
ATE394102T1 (de) 2008-05-15
NO20026010D0 (no) 2002-12-13
BG107376A (bg) 2003-09-30
HK1053124A1 (en) 2003-10-10
ZA200209412B (en) 2004-02-19
AU2001266505A1 (en) 2002-01-08
WO2002000649A1 (en) 2002-01-03
MXPA02011974A (es) 2004-09-06
EE200200715A (et) 2004-08-16
CN1496364A (zh) 2004-05-12
NO20026010L (no) 2002-12-13
SK18102002A3 (sk) 2003-07-01
KR20030014411A (ko) 2003-02-17
IL153246A0 (en) 2003-07-06

Similar Documents

Publication Publication Date Title
AR030432A1 (es) Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica.
AR038476A1 (es) Derivados de quinazolina
AR037881A1 (es) Uso de derivados de oxindol
AR045691A1 (es) Derivados de heteroarilamida como receptores antagonistas p2x7 y sus usos
ES2128791T3 (es) Derivados espirocetales, composiciones que los contienen y su uso como agentes terapeuticos.
HUP0400365A2 (hu) 3-Fluor-pirrolidinek, mint cukorbetegség elleni szerek és a vegyületeket tartalmazó gyógyszerkészítmények
AR046779A1 (es) Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer.
AR038052A1 (es) Derivados de quinazolina como inhibidores de auroraquinasas
ATE330959T1 (de) Allosterische adenosin-rezeptor-modulatore
AR025735A1 (es) Compuestos terapeuticos
ECSP066314A (es) Derivados piridilo y su uso como agentes terapéuticos
AR032136A1 (es) Compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas
CR8859A (es) Derivados de piridina
HUP0300894A2 (hu) Szubsztituált béta-karbolinok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626572A (en) Heterocyclic derivatives and their use as therapeutic agents
HUP0105414A2 (hu) Pirrolo-izokinolin-, azepino- és diazepino-indol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
SE0102438D0 (sv) New compounds
NO963053L (no) Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav
CY1112178T1 (el) Παραγωγα πιπεραζινης και χρηση αυτων ως θεραπευτικων παραγοντων
AR088808A2 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
AR061918A1 (es) Compuesto biciclico que contiene nitrogeno, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
EE200100491A (et) Tetrahüdropüraani derivaadid, nende saamine ja kasutamine ravimainetena ning neid sisaldav farmatseutiline kompositsioon
PE20020759A1 (es) Derivados de bencilamina con base prolina como inhibidores de trombina
HUP0203184A2 (hu) Izoxazolkarboxamid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
FA Abandonment or withdrawal